Contact
Direct contact with the scientific team.
Enquiries concerning a screening project, the MuTaTo programme or a scientific collaboration are reviewed by the scientists who would direct the work.
Write directly
office@aebi-bio.comimorad@gmail.comBased in Israel. The team is small and correspondence volume is high: every initial enquiry is read, but a reply cannot be guaranteed.
What happens next
- 01Target descriptionThe protein, the intended effect on it, and any constraints already known.
- 02Feasibility assessmentAn objective assessment of whether SoAP is suited to that target, and what the screening would involve.
- 03Proposed planScreening strategy, timeline and budget. Work begins only on written agreement.
Please note
AEBi is a research company. No clinic is operated, no individual medical case can be advised upon, and there is currently no clinical trial of MuTaTo. Referrals and treatment are not available.
Partners
Pharma, biotech, research organisations.
AEBi engages in fee-for-service projects, sponsored research and broader strategic collaborations, and welcomes discussion of protein targets for which novel peptide binders are required.